GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (FRA:EZB) » Definitions » Cyclically Adjusted Revenue per Share

Enzo Biochem (FRA:EZB) Cyclically Adjusted Revenue per Share : €1.96 (As of Apr. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Enzo Biochem's adjusted revenue per share for the three months ended in Apr. 2024 was €0.146. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.96 for the trailing ten years ended in Apr. 2024.

During the past 12 months, Enzo Biochem's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -2.80% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 0.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Enzo Biochem was 7.30% per year. The lowest was -3.20% per year. And the median was 3.50% per year.

As of today (2024-06-19), Enzo Biochem's current stock price is €1.02. Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2024 was €1.96. Enzo Biochem's Cyclically Adjusted PS Ratio of today is 0.52.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzo Biochem was 4.64. The lowest was 0.48. And the median was 1.32.


Enzo Biochem Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Enzo Biochem's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cyclically Adjusted Revenue per Share Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.30 2.08 2.09 2.30 1.95

Enzo Biochem Quarterly Data
Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.95 2.09 1.95 1.96

Competitive Comparison of Enzo Biochem's Cyclically Adjusted Revenue per Share

For the Diagnostics & Research subindustry, Enzo Biochem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cyclically Adjusted PS Ratio falls into.



Enzo Biochem Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enzo Biochem's adjusted Revenue per Share data for the three months ended in Apr. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Apr. 2024 (Change)*Current CPI (Apr. 2024)
=0.146/131.7762*131.7762
=0.146

Current CPI (Apr. 2024) = 131.7762.

Enzo Biochem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201407 0.418 100.520 0.548
201410 0.440 100.176 0.579
201501 0.442 98.604 0.591
201504 0.484 99.824 0.639
201507 0.507 100.691 0.664
201510 0.486 100.346 0.638
201601 0.486 99.957 0.641
201604 0.504 100.947 0.658
201607 0.512 101.524 0.665
201610 0.516 101.988 0.667
201701 0.533 102.456 0.686
201704 0.545 103.167 0.696
201707 0.475 103.278 0.606
201710 0.488 104.070 0.618
201801 0.457 104.578 0.576
201804 0.437 105.708 0.545
201807 0.413 106.324 0.512
201810 0.392 106.695 0.484
201901 0.359 106.200 0.445
201904 0.368 107.818 0.450
201907 0.390 108.250 0.475
201910 0.384 108.577 0.466
202001 0.367 108.841 0.444
202004 0.325 108.173 0.396
202007 0.356 109.318 0.429
202010 0.508 109.861 0.609
202101 0.538 110.364 0.642
202104 0.562 112.673 0.657
202107 0.431 115.183 0.493
202110 0.472 116.696 0.533
202201 0.621 118.619 0.690
202204 0.498 121.978 0.538
202207 -1.092 125.002 -1.151
202210 0.148 125.734 0.155
202301 0.143 126.223 0.149
202304 0.138 127.992 0.142
202307 0.163 128.974 0.167
202310 0.147 129.810 0.149
202401 0.156 130.124 0.158
202404 0.146 131.776 0.146

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Enzo Biochem  (FRA:EZB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enzo Biochem's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.02/1.96
=0.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Enzo Biochem was 4.64. The lowest was 0.48. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Enzo Biochem Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (FRA:EZB) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.

Enzo Biochem (FRA:EZB) Headlines

No Headlines